Table 6.
Exosomes and Their Components as Therapeutic Targets for Cervical Cancer.
| Biomarker | Trend | Type | Source | Recipient cells | Functions | Mechanisms | Application | Ref |
|---|---|---|---|---|---|---|---|---|
| miR-223 | Increase | miRNA | Cancer cells | Cancer cells | Enhance migration, tumor growth | TGFBR3/HMGCS1 | Therapeutic target/nanocarrier | 111 |
| miR-106a, miR-106b | Decrease | miRNA | Cancer cells | Cancer cells | Inhibit chemoresistance | SIRT1 | Therapeutic target/ nanocarrier | 112 |
| miR-663b | Increase | miRNA | Cancer cells | Cancer cells | Enhance EMT, migration | MGAT3 | Therapeutic target | 113 |
| miR-663b | Increase | miRNA | Cancer cells | Cancer cells/endothelial cells | Enhance tumor growth, angiogenesis | VCL | Therapeutic target | 114 |
| miR-22 | Decrease | miRNA | Cancer cells | Cancer cells | Inhibit radiosensitivity | MYCBP /hTERT | Therapeutic target/nanocarrier | 115 |
| miR-221-3p | Increase | miRNA | Cancer cells | Cancer cells/endothelial cells | Enhance migration, angiogenesis | MAPK10 | Therapeutic target/nanocarrier | 116 |
| miR-221-3p | Increase | miRNA | Cancer cells | HLECs | Enhance lymphangiogenesis, lymphatic metastasis | VASH1 | Therapeutic target/ nanocarrier | 117 |
| miR-320a | Increase | miRNA | Cancer cells | Cancer cells | Enhance chemoresistance, tumor growth | MCL1 | Therapeutic target/nanocarrier | 118 |
| miR-423-3p | Increase | miRNA | Cancer cells | Cancer cells/macrophages | Enhance M2 polarization, chemoresistance, tumor growth | — | Therapeutic target | 119 |
| miR-1323 | Increase | miRNA | CAFs | Cancer cells | Enhance proliferation, migration, invasion, inhibit radiosensitivity | PABPN1/IGF2BP1/GSK-3β/Wnt/β-catenin | Therapeutic target | 120 |
| miR-142-5p | Increase | miRNA | Cancer cells | HLECs | Suppress and exhaust CD8+ T cells | IDO/ARID2–DNMT1–IFN-γ | Diagnosis/therapeutic target | 121 |
| miR-1468-5p | Increase | miRNA | Cancer cells | HLECs | Enhance lymphangiogenesis | HMBOX1/ JAK2/STAT3 | Therapeutic target | 122 |
| miR-155-5p | Increase | miRNA | HIV-1 infected T cells | Cancer cells | Enhance proliferation, migration, invasion | ARID2/ERCC5/NF-κB | Therapeutic target | 123 |
| lncRNA HNF1A-AS1 | Increase | lncRNA | Cancer cells | Cancer cells | Enhance proliferation, tumor growth and Inhibit apoptosis | miR-34b/TUFT1 | Therapeutic target | 124 |
| lncRNA UCA1 | Increase | lncRNA | Cancer cells | CSCs | Enhance proliferation, migration, invasion, tumor growth | miR-122-5p/SOX2 | Therapeutic target | 125 |
| lncRNA LINC01035 | Increase | lncRNA | Cancer cells | Cancer cells | Enhance migration, invasion, tumor growth | KHSRP | Therapeutic target | 126 |
| lncRNA PDHB-AS | Decrease | lncRNA | HKF/cancer cells | Cancer cells | Inhibited proliferation, invasion, EMT, and chemoresistance | miR-582-5p/Wnt/β-catenin | Therapeutic target | 127 |
| lncRNA MALAT1 | Increase | lncRNA | Cancer cells | Cancer cells | Promoted proliferation, chemoresistance, inhibited apoptosis | STAT3/PI3K/AKT | Therapeutic target | 128 |
| lnc LRRC75A-AS1 | Increase | lncRNA | M2 macrophages | Cancer cells | Promoted proliferation, migration, invasion, EMT, tumor growth, metastasis | miR-429 /SIX1/STAT3/MMP-9 | Therapeutic target | 129 |
| circ_0074269 | Increase | circRNA | Cancer cells | Cancer cells | Increase proliferation, migration, chemoresistance, induce apoptosis | miR-485-5p/TUFT1 | Therapeutic target | 130 |
| Circ_0006646 | Increase | circRNA | Cancer cells | Cancer cells | Increase proliferation, migration, invasion, tumor growth, metastasis | miR-758-3p/RRM2 | Therapeutic target | 131 |
| — | — | — | Paclitaxel loading WJ-MSC’s exosomes | Cancer cells | Induce apoptosis, Suppress EMT signaling | — | Therapeutic target/nanocarrier | 132 |
HLECs: human lymphatic endothelial cells; HKF: human keloid fibroblasts; WJ-MSC: Wharton jelly-derived mesenchymal stem cells; EMT: epithelial–mesenchymal transition.